Acceder Registro /

JOSÉ VALVERDE MOLINA

Buscador

Castilla-Martinez M, Andujar-Espinosa R, Flores-Martin I, Reyes Cotes MH, Cabrejos-Perotti S, Miralles-Lopez JC, Carbonell-Martinez A, Bravo-Gutierrez FJ, Valverde-Molina J, Perez-Fernandez V; RE-ASGRAMUR GROUP. Early Effectiveness of Dupilumab in Patients With Type 2 Severe Asthma: A Prospective Real-Life Study. J Investig Allergol Clin Immunol. 2023 Apr 18;33(2):126-128. doi: 10.18176/jiaci.0872. Epub 2022 Nov 24. No abstract available. PubMed PMID: 36420744.
AÑO: 2023; IF: 7.2
Valverde-Molina J, Garcia-Marcos L. Microbiome and Asthma: Microbial Dysbiosis and the Origins, Phenotypes, Persistence, and Severity of Asthma. Nutrients. 2023 Jan 17;15(3):486. doi: 10.3390/nu15030486. PubMed PMID: 36771193; PubMed Central PMCID: PMC9921812.
AÑO: 2023; IF: 6.706
Diaz-Garcia C, Valverde-Molina J, Martinez-Gimeno A, Anton-Pacheco Sanchez JL. Quality of life in children with diseases causing central airway obstruction: Reliability and validity of the TAPQOL questionnaire. Pediatr Pulmonol. 2023 Jan;58(1):279-287. doi: 10.1002/ppul.26198. Epub 2022 Oct 17. PubMed PMID: 36207999.
AÑO: 2023; IF: 3.1
Valverde-Molina J, Fernandez-Nieto M, Torres-Borrego J, Lozano Blasco J, de Mir-Messa I, Blanco-Aparicio M, Nieto A, Figuerola Mulet J, Moure AL, Sanchez-Herrero MG, Sanchez-Garcia S. Transition of Adolescents With Severe Asthma From Pediatric to Adult Care in Spain: The STAR Consensus. J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):179-189. doi: 10.18176/jiaci.0780. Epub 2022 Jan 14. PubMed PMID: 35029151.
AÑO: 2023; IF: 7.2
Miralles-Lopez JC, Andujar-Espinosa R, Bravo-Gutierrez FJ, Castilla-Martinez M, Flores-Martin I, Alemany-Frances ML, Pajaron-Fernandez MJ, Mora-Gonzalez A, Cabrejos-Perotti S, El-Molaka Z, Meseguer-Arce J, Aviles-Ingles MJ, Valverde-Molina J, Perez-Fernandez V; RE-ASGRAMUR Group. Analysis of response of severe eosinophilic asthmatic patients to benralizumab. Allergol Immunopathol (Madr). 2022 Nov 1;50(6):163-168. doi: 10.15586/aei.v50i6.704. eCollection 2022. PubMed PMID: 36335460.
AÑO: 2022; IF: 1.8

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R